SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst case 3066). NNVs for surgical patients remained favourable at a range of SARS-CoV-2 incidence rates in sensitivity analysis modelling. Globally, prioritizing preoperative vaccination of patients needing elective surgery ahead of the general population could prevent an additional 58 687 (best case 115 007, worst case 20 177) COVID-19-related deaths in 1 year. Conclusion As global roll out of SARS-CoV-2 vaccination proceeds, patients needing elective surgery should be prioritized ahead of the general population

Клініко-гемодинамічний ефект фруктозо-1,6-дифосфату и фосфокреатину у хворих на гострий коронарний синдром

One of the promising areas of treating cardiovascular diseases is the use of drugs with metabolic action. Metabolic drugs have not only the ability to improve myocardial energy metabolism, but also strong antioxidant properties.Одним из перспективных направлений терапии сердечно-сосудистых заболеваний является применение препаратов с метаболическим действием. Метаболические препараты обладают не только способностью улучшать энергетический обмен миокарда, но и выраженными антиоксидантными свойствами.Одним із перспективних напрямків терапії серцево-судинних захворювань є застосування препаратів метаболічної дії. Метаболічні препарати володіють не лише здатністю покращувати енергетичний обмін міокарда, але й мають виражені антиоксидантні властивості